Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer.

BMC cancer - 20 Apr 2021

Manzano Ramon Gonzalez, Catalan-Latorre Ana, Brugarolas Antonio

Abstract excerpt

BACKGROUND: Muscle invasive urothelial bladder carcinoma (MIBC) present RB1 and TP53 somatic alterations in a variable percentage of tumors throughout all molecular subtypes. MIBCs with neuroendocrine features have a high response rate to immunity checkpoint inhibitors (ICIs). Whether the presence of somatic co-alterations in these 2 genes in MIBCs is relevant to their responsiveness to ICIs is not known....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Immune Checkpoint Inhibitors
Share to Kaplan-Meier Estimate

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neoplasm Staging

Share to Proportional Hazards Models

Share to Retinoblastoma Binding Proteins

Share to Tumor Microenvironment

Share to Ubiquitin-Protein Ligases

Share to Urinary Bladder Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 33879103
DOI: 10.1186/s12885-021-08078-y
PMCID: PMC8056512

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer.PMID 33879103Read ↗

DNA damage repair gene mutations and their association with tumor immune regulatory gene expression in muscle invasive bladder cancer subtypesSemantic proximity Read ↗

Urothelial Bladder Carcinomas with High Tumor Mutation Burden Have a Better Prognosis and Targetable Molecular Defects beyond Immunotherapies.Semantic proximity Read ↗

Predicting immunotherapy response in advanced bladder cancer: a meta-analysis of six independent cohortsSemantic proximity Read ↗

Multi-omics Perspective on the Tumor Microenvironment based on PD-L1 and CD8 T-Cell Infiltration in Urothelial CancerSemantic proximity Read ↗

Tumor Immune Infiltration as a Predictor of Response to Neoadjuvant Chemo-Immunotherapy in Muscle-Invasive Bladder Cancer: An Integrative TCGA AnalysisSemantic proximity Read ↗

A Five-Gene Stromal-EMT Signature Predicts Prognosis, Immunotherapy Resistance, and Therapeutic Vulnerability in Bladder CancerSemantic proximity Read ↗

Novel Genetic Subtypes of Urothelial Carcinoma With Differential Outcomes on Immune Checkpoint Blockade.Semantic proximity Read ↗

Defining muscle-invasive bladder cancer immunotypes by introducing tumor mutation burden, CD8+ T cells, and molecular subtypesSemantic proximity Read ↗

A TP53-Associated Immune Prognostic Signature for the Prediction of Overall Survival and Therapeutic Responses in Muscle-Invasive Bladder Cancer.Semantic proximity Read ↗

Defining muscle-invasive bladder cancer immunotypes by introducing tumor mutation burden, CD8+ T cells, and molecular subtypes.Semantic proximity Read ↗

Contribution of systemic and somatic factors to clinical response and resistance in urothelial cancer: an exploratory multi-omic analysisSemantic proximity Read ↗

ATM Mutations Benefit Bladder Cancer Patients Treated With Immune Checkpoint Inhibitors by Acting on the Tumor Immune MicroenvironmentSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.